Putnam Investments’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $43.2M | Sell |
106,049
-3,079
| -3% | -$1.14M | 0.06% | 153 |
|
|
2023
Q3 | $37.9M | Sell |
109,128
-1,578
| -1% | -$552K | 0.06% | 154 |
|
|
2023
Q2 | $39M | Sell |
110,706
-8,237
| -7% | -$2.78M | 0.06% | 156 |
|
|
2023
Q1 | $37.5M | Sell |
118,943
-15,029
| -11% | -$4.51M | 0.06% | 162 |
|
|
2022
Q4 | $38.7M | Sell |
133,972
-9,309
| -6% | -$2.84M | 0.07% | 157 |
|
|
2022
Q3 | $41.5M | Sell |
143,281
-45,221
| -24% | -$13M | 0.08% | 150 |
|
|
2022
Q2 | $53.1M | Buy |
188,502
+19,420
| +11% | +$5.2M | 0.1% | 141 |
|
|
2022
Q1 | $44.1M | Sell |
169,082
-12,490
| -7% | -$2.96M | 0.07% | 158 |
|
|
2021
Q4 | $39.9M | Sell |
181,572
-337,467
| -65% | -$65.6M | 0.06% | 178 |
|
|
2021
Q3 | $94.1M | Sell |
519,039
-11,020
| -2% | -$2.15M | 0.15% | 136 |
|
|
2021
Q2 | $107M | Buy |
530,059
+48,639
| +10% | +$10.2M | 0.17% | 126 |
|
|
2021
Q1 | $103M | Sell |
481,420
-893,233
| -65% | -$196M | 0.17% | 127 |
|
|
2020
Q4 | $325M | Buy |
1,374,653
+155,467
| +13% | +$35.7M | 0.58% | 49 |
|
|
2020
Q3 | $332M | Sell |
1,219,186
-195,949
| -14% | -$54.1M | 0.65% | 38 |
|
|
2020
Q2 | $411M | Buy |
1,415,135
+45,824
| +3% | +$12.4M | 0.87% | 28 |
|
|
2020
Q1 | $326M | Buy |
1,369,311
+254,079
| +23% | +$58.3M | 0.85% | 27 |
|
|
2019
Q4 | $244M | Sell |
1,115,232
-126,087
| -10% | -$25.5M | 0.5% | 54 |
|
|
2019
Q3 | $210M | Buy |
1,241,319
+95,195
| +8% | +$16.8M | 0.47% | 59 |
|
|
2019
Q2 | $210M | Sell |
1,146,124
-55,896
| -5% | -$9.77M | 0.47% | 61 |
|
|
2019
Q1 | $221M | Sell |
1,202,020
-262,303
| -18% | -$48.4M | 0.51% | 56 |
|
|
2018
Q4 | $243M | Sell |
1,464,323
-142,737
| -9% | -$24.7M | 0.64% | 40 |
|
|
2018
Q3 | $310M | Sell |
1,607,060
-144,700
| -8% | -$25.8M | 0.67% | 38 |
|
|
2018
Q2 | $298M | Buy |
1,751,760
+39,166
| +2% | +$6.07M | 0.68% | 36 |
|
|
2018
Q1 | $279M | Buy |
1,712,594
+260,431
| +18% | +$42.5M | 0.65% | 30 |
|
|
2017
Q4 | $218M | Buy |
1,452,163
+372,722
| +35% | +$55.2M | 0.49% | 53 |
|
|
2017
Q3 | $164M | Buy |
1,079,441
+1,074,483
| +21,672% | +$162M | 0.38% | 72 |
|
|
2017
Q2 | $639K | Sell |
4,958
-397,445
| -99% | -$47.8M | ﹤0.01% | 965 |
|
|
2017
Q1 | $44M | Buy |
402,403
+5,838
| +1% | +$514K | 0.1% | 176 |
|
|
2016
Q4 | $29.2M | Sell |
396,565
-3,040
| -0.8% | -$247K | 0.07% | 229 |
|
|
2016
Q3 | $34.9M | Sell |
399,605
-145,571
| -27% | -$13.8M | 0.08% | 209 |
|
|
2016
Q2 | $46.9M | Buy |
545,176
+357,176
| +190% | +$30.9M | 0.11% | 183 |
|
|
2016
Q1 | $14.9M | Sell |
188,000
-400
| -0.2% | -$36.2K | 0.04% | 357 |
|
|
2015
Q4 | $23.7M | Sell |
188,400
-490,806
| -72% | -$59.2M | 0.05% | 284 |
|
|
2015
Q3 | $70.7M | Buy |
679,206
+411,642
| +154% | +$52.9M | 0.16% | 143 |
|
|
2015
Q2 | $33M | Sell |
267,564
-91,356
| -25% | -$11.5M | 0.07% | 259 |
|
|
2015
Q1 | $42.3M | Sell |
358,920
-15,156
| -4% | -$1.82M | 0.08% | 228 |
|
|
2014
Q4 | $44.4M | Sell |
374,076
-540,898
| -59% | -$60.9M | 0.09% | 224 |
|
|
2014
Q3 | $103M | Sell |
914,974
-79,581
| -8% | -$7.58M | 0.22% | 107 |
|
|
2014
Q2 | $94.2M | Buy |
994,555
+410,342
| +70% | +$28.8M | 0.2% | 120 |
|
|
2014
Q1 | $41.3M | Sell |
584,213
-33,398
| -5% | -$2.65M | 0.09% | 214 |
|
|
2013
Q4 | $45.9M | Buy |
617,611
+733
| +0.1% | +$51K | 0.11% | 202 |
|
|
2013
Q3 | $46.8M | Buy |
616,878
+119,438
| +24% | +$9.5M | 0.13% | 187 |
|
|
2013
Q2 | $39.7M | Buy |
+497,440
| New | +$36.6M | 0.12% | 196 |
|
Other funds holding VRTX
Putnam Investments's VRTX Position: Q4 2023 in Review
Putnam Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q4 2023, selling an estimated $1.14M and leaving 106,049 shares worth $43.2M. The position accounts for 0.06% of the portfolio, ranked #153.
Putnam Investments first reported a position in VRTX in Q2 2013 and has held it in 43 quarters since. The position peaked at $411M in Q2 2020. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.
- Putnam Investments held 106,049 shares of Vertex Pharmaceuticals worth $43.2M as of Q4 2023.
- Putnam Investments sold 3,079 Vertex Pharmaceuticals shares in Q4 2023, an estimated $1.14M.
- Vertex Pharmaceuticals made up 0.06% of Putnam Investments's portfolio in Q4 2023, its #153 holding.
- Putnam Investments first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Putnam Investments's Vertex Pharmaceuticals position peaked at $411M in Q2 2020.
- 1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.
Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.